This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AGIL-AADC

Agilis Biotherapeutics, Inc.

Drug Names(s): AADC Gene Therapy, AGILAADC

Description: AADC Gene Therapy is an investigative gene therapy with adeno-associated virus (AAV) delivering the human aromatic L-amino acid decarboxylase (AADC) gene.

Deal Structure: Agilis and NTU
In January 2016, Agilis Biotherapeutics entered into an exclusive worldwide license agreement with National Taiwan University (NTU) for the treatment of AADC deficiency.


AGIL-AADC News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug